Markets:

Overview

News

Currencies

International

Treasuries

REGENXBIO Inc. - Common Stock (NQ:RGNX)

14.99 -0.25 (-1.61%)

Streaming Delayed Price Updated: 3:55 PM EST, Jan 8, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about REGENXBIO Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

This Gene Therapy Player Duchenne Data Is Impressive, Analyst Upgrades REGENXBIO ↗

March 08, 2024

REGENXBIO's promising gene therapy advancements! RBC Capital Markets upgraded REGENXBIO (RGNX), citing impressive RGX-202 trial results in Duchenne patients.

Via Benzinga

Beyond The Numbers: 4 Analysts Discuss Regenxbio Stock ↗

March 06, 2024

Via Benzinga

REGENXBIO's Muscle Wasting Disorder Drug Shows Strength, Improved Motor Function, Stock Soars ↗

March 05, 2024

Latest updates on safety and efficacy in the Phase 1/2 AFFINITY DUCHENNE trial for Duchenne muscular dystrophy. Positive results, no serious adverse events. Expect pivotal dose determination by...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

March 05, 2024

Via Benzinga

Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday ↗

March 01, 2024

U.S. stocks were higher, with the Nasdaq Composite gaining around 0.5% on Friday.

Via Benzinga

Topics Stocks

Regenxbio: Q4 Earnings Insights ↗

February 27, 2024

Via Benzinga

Earnings Scheduled For February 27, 2024 ↗

February 27, 2024

Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million.

Via Benzinga

Why Zscaler Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

March 01, 2024

Shares of Zscaler, Inc. (NASDAQ: ZS) shares fell sharply during Friday’s session following second-quarter results.

Via Benzinga

A Preview Of Regenxbio's Earnings ↗

February 26, 2024

Via Benzinga

Gene Therapy Player REGENXBIO's RGX-121 Marks Success In Trial, Yet Faces Challenges In A Crowded Market: Analyst ↗

February 12, 2024

Insights from Wedbush analysts about the clinical effectiveness of REGENXBIO's RGX-202, market potential, and challenges posed by competitors like Sarepta Therapeutics and Pfizer.

Via Benzinga

Earnings Preview For Regenxbio ↗

November 07, 2023

Via Benzinga

What 4 Analyst Ratings Have To Say About Regenxbio ↗

October 04, 2023

Via Benzinga

The Latest Analyst Ratings for Regenxbio ↗

August 29, 2023

Via Benzinga

Earnings Preview: Regenxbio ↗

August 01, 2023

Via Benzinga

The One-Minute Market Report - Sunday, Feb. 11 ↗

February 11, 2024

In this brief market report, we will take a look at the various asset classes, sectors, equity categories, exchange-traded funds, and stocks that moved the market higher, as well as the market segments...

Via Talk Markets

Jim Cramer Says Investors Should Look Beyond Apple, Meta And Other Magnificent 7 Stocks: 'You Might Be Missing Out On Some Huge Gains' ↗

February 08, 2024

Jim Cramer, the host of CNBC's "Mad Money," has suggested that investors should look beyond the Magnificent Seven tech stocks for potential high-yield investments.

Via Benzinga

Why Is Blindness Focused-Adverum Biotechnologies Stock Trading Lower Today? ↗

February 08, 2024

Adverum Biotechnologies' Ixo-vec gene therapy for wet AMD. Preliminary LUNA Phase 2 trial data show safety, efficacy, and significant treatment burden reduction.

Via Benzinga

Why Is Gene Therapy-Focused REGENXBIO Stock Trading Higher Today? ↗

February 07, 2024

REGENXBIO's progress in Duchenne muscular dystrophy and MPS II treatment trials. Interim results for RGX-202 in Phase 1/2 trial and significant milestones achieved in Phase 1/2/3 trial with RGX-121.

Via Benzinga

What 6 Analyst Ratings Have To Say About Regenxbio ↗

July 12, 2023

Via Benzinga

5 Analysts Have This to Say About Regenxbio ↗

June 20, 2023

Via Benzinga

Why Container Store Group Shares Are Trading Lower By Around 23%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

February 07, 2024

Shares of The Container Store Group, Inc. (NYSE: TCS) shares fell sharply during Wednesday’s session following weak quarterly results.

Via Benzinga

Chipotle Posts Upbeat Earnings, Joins Cirrus Logic, Emerson Electric, Carlyle Group And Other Big Stocks Moving Higher On Wednesday ↗

February 07, 2024

U.S. stocks traded higher, with the Dow Jones gaining around 150 points on Wednesday.

Via Benzinga

Topics Stocks

Ocular Gene Therapy: Regenxbio Data Shows Consistent Preservation Of Visual Acuity, Retinal Thickness ↗

January 17, 2024

Regenxbio's latest trial data on ABBV-RGX-314 reveal 80% reduction in injection rate, 50% injection-free, and no intraocular inflammation.

Via Benzinga

Progress Software Posts Strong Q4 Results, Joins Impinj, REGENXBIO And Other Big Stocks Moving Higher In Wednesday's Pre-Market Session ↗

January 17, 2024

U.S. stock futures were lower this morning, with the Dow Jones futures falling more than 100 points on Wednesday. Shares of Progress Software Corporation (NASDAQ: PRGS) rose in pre-market trading as...

Via Benzinga

Topics Stocks

Boeing, Pacific Biosciences of California And Other Big Stocks Moving Lower On Monday ↗

January 08, 2024

U.S. stocks traded mixed, with the Dow Jones index falling around 80 points on Monday. Shares of The Boeing Company (NYSE: BA) fell during Friday’s session after an exit door blew out of a 737 aircraft...

Via Benzinga

Topics Stocks

12 Health Care Stocks Moving In Monday's After-Market Session ↗

October 30, 2023

Via Benzinga

Why RxSight Shares Are Trading Higher By 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

January 08, 2024

Shares of RxSight, Inc. (NASDAQ: RXST) rose sharply during Monday’s session after the company issued preliminary FY23 and FY24 revenue guidance above estimates. Also, Needham maintained a Buy rating on...

Via Benzinga

RegenXbio's Potential Blockbuster: Analyst is Bullish On Stock Citing Potential Gains From AAV Gene Therapies Resurgence ↗

June 20, 2023

Baird has initiated coverage on RegenXbio Inc (NASDAQ: RGNX) with an Outperform rating and a

Via Benzinga

Stocks That Hit 52-Week Lows On Thursday ↗

October 05, 2023

On Thursday, 369 companies hit new 52-week lows.

Via Benzinga

Stocks That Hit 52-Week Lows On Monday ↗

September 11, 2023

Monday's session saw 175 companies set new 52-week lows.

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.